Emerald Health Therapeutics Secures Proprietary Extraction Technology and Extraction Capabilities in Agreement with Indena
05 Februar 2019 - 1:00PM
Emerald receives certain exclusive rights
to established Phytosome® technology to enhance
absorption and bioavailability of cannabinoid products
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH;
OTCQX:EMHTF) has entered into a license with Indena S.p.A.
(“Indena”) of Milan, Italy, bearing certain exclusivity rights in
Canada to use Indena’s cannabidiol (“CBD”) extraction technology,
and contract manufacturing services for CBD extraction. In
addition, Emerald has obtained exclusive use of Indena’s
proprietary Phytosome® technology for the purpose of developing
novel cannabinoid-based products with superior utility, subject to
a minimum volume agreement.
This collaboration leverages Indena’s
decades-long global presence in the plant extraction industry and
botanical experience in phytochemical research. Indena is the
world’s leading company in the identification, development, and
production of plant-derived active ingredients for the
pharmaceutical, health food, and personal care industries. It is
adapting an existing proprietary extraction process to facilitate
hemp extraction and will exclusively provide Emerald in Canada with
this highly optimized process for extracting and isolating CBD to
manufacture cannabinoid-based products. With multiple international
large-scale extraction facilities, Indena will be the exclusive
third party manufacturing supplier of CBD for Emerald.
Emerald will use this CBD in its production of certain product
lines.
Emerald and Indena have also established a
research collaboration to assess the use of Indena’s Phytosome®
technology in combination with various cannabinoids. The agreement
provides Emerald with exclusive access to certain of Indena’s
scientifically validated, commercially available Phytosome®
formulations and plant-based technology that is designed to enhance
solubility of compounds that are usually poorly absorbed by the
body, such as cannabinoids. For Emerald, evaluating and
securing superior technologies like Phytosome® is an important
aspect of its objective to develop differentiated and effective
cannabinoid-based products to improve human health.
“Emerald is one of the few Licensed Producers in
Canada focused on applying proprietary innovation to improve
the medical applications of cannabinoids, which is fully aligned
with Indena’s scientific approach to phytochemical research,” said
Stefano Togni, Business Development and Licensing Director of
Indena. “We believe that both companies’ approaches to quality and
innovation will create an exciting partnership that will add value
to the industry and better serve patients and consumers who look
for excellence in their products and predictive health
outcomes.”
“In my many years as a practicing naturopathic
physician, Indena has been the gold standard in plant extraction in
the natural health products industry,” said Dr. Gaetano Morello,
Chair of Emerald’s scientific advisory board and CEO of Emerald
Health Naturals. “By gaining access to their technology, know-how,
and expertise, Emerald is propelling itself as a leader in the
innovation of next generation CBD-based products.”
“Reinventing processes and replicating existing
expertise does not make sense to us when we can work with the best.
We welcome Indena’s decision to work closely with our team,” added
Dr. Avtar Dhillon, President and Executive Chairman of Emerald
Health Therapeutics. “We aim to bring together unbeatable
global expertise, technology and infrastructure to innovate and
commercialize value-added cannabinoid-based products, and we will
do this with both internal resources and industry-leading
partners.
“Indena is one of the oldest and most
established extraction businesses in the world. They have served
international pharmaceutical companies with natural anti-cancer
ingredients. They are leaders in nutraceutical products. With
multiple extraction-related deals announced, our comprehensive and
cohesive international strategy for cannabis and hemp extraction is
unfolding. We look forward to impactful cannabinoid product
development advancements in 2019.”
About Indena
Indena is the leading company dedicated to
the identification, development and production of high quality
active principles derived from plants for use in the
pharmaceutical, health food and personal care industries. Backed up
by almost a century of botanical experience, the company holds more
than 120 primary patents, has published more than 700 scientific
studies and co-operates with the world’s most prestigious
universities and private research institutions. Indena employs
about 800 staff, investing around 10% of its annual turnover in
research, making this activity the key to its success.
Headquartered in Milan, Indena has 5 production sites and 5
international branches throughout the world and manages sales in
more than 70 countries. The Company’s experts communicate and
interact constantly with the major international regulatory
authorities such as WHO, EMA, FDA and ESCOP, and cooperate on the
update of all the main pharmacopoeias. Today, Indena also supplies
capacity and expertise for custom manufacturing services and
related key technologies. In particular, the company has expanded
its offering with a new kilolab to handle semisynthetic and totally
synthetic active pharmaceutical ingredients (API) that require high
containment, ie. occupational exposure limit (OEL) of 20 μg/m3.
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. is a
Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms
joint venture in BC is completing the conversion of its 1.1 million
square foot (25 acre) greenhouse for cannabis cultivation in the
Lower Mainland and its Verdélite operation in Québec is completing
the build-out of its 75,000 square feet indoor cultivation
facility. Commercial production is expanding in both facilities.
Emerald secured over 500 acres of hemp harvest in 2018 and has
contracted for approximately 1000 acres in 2019 to 2022 with the
objective of extracting low-cost cannabidiol (CBD). Emerald’s team
is highly experienced in life sciences, product development,
large-scale agri-business, and marketing, and is focused on
developing proprietary, value-added cannabis products for medical
and adult-use customers. Emerald is part of the Emerald
Health group, which represents a broad array of companies
focused on developing pharmaceutical, botanical, and nutraceutical
products developed to provide wellness and medical benefits by
interacting with the human body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more
information or contact:Rob Hill, Chief Financial Officer(800) 757
3536 Ext. #5
Investor Relations (800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include completion of the joint venture and obtaining exclusive
Canadian distribution rights; establishing a brand; launch of the
Endo line in 2019; sales of non-cannabis products; development of
sales channels; expansion of permitted sales of cannabis;
leveraging of distribution channels; development of new products;
the benefits and effects of certain products; production capacity
of various facilities; and receipt of hemp deliveries.
Actual results may vary from forward-looking
statements. We cannot guarantee that any forward-looking statement
will materialize, and readers are cautioned not to place undue
reliance on these forward-looking statements. These forward-looking
statements involve risks and uncertainties related to, among other
things, failure to obtain necessary financing; failure to settle
final documentation; failure to obtain regulatory approvals;
results of production and sale activities; results of scientific
research; regulatory changes; changes in prices and costs of
inputs; demand for labour; demand for products; future distribution
agreements; failure of counterparties to perform contractual
obligations; as well as the risk factors described in the Company’s
annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
Von Jun 2023 bis Jun 2024